Sebela Pharmaceuticals, Inc.

Company Summary

Sebela Pharmaceuticals, Inc. (“Sebela”) is a privately held, US-focused commercialization and development organization that markets pharmaceuticals across three therapeutic franchises; Gastroenterology, Women’s Health, and Dermatology. Sebela's strategy is to leverage its 110 member internal sales force by acquiring sub-optimally marketed products, commercializing new products and driving increased penetration of existing products.

Transaction Overview

1 May, 2018: Metalmark completed a minority investment in Sebela (via a convertible preferred equity security), combining with debt financing and equity from existing Sebela shareholders to finance the acquisition of Braintree.
Braintree Laboratories, Inc. ("Braintree"), a privately held, fully integrated specialty pharmaceutical company. In addition to being a market leader in the colonoscopy preparation market, Braintree also has an attractive portfolio of products in the FDA approval pipeline.

‍

Significance of the Transaction

The acquisition of Braintree presents considerable strategic fit with Sebela's focus in Gastroenterology, while the combination of the two companies is expected to generate meaningful synergies.

Healthios Role

If you would like to learn more information about this transaction contact us below.

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Mergers & Acquisitions

Sebela Pharmaceuticals, Inc.

Has acquired

The undersigned acted as strategic advisor to Metalmark Capital